Literature DB >> 24648548

Human cathelicidin LL-37 resistance and increased daptomycin MIC in methicillin-resistant Staphylococcus aureus strain USA600 (ST45) are associated with increased mortality in a hospital setting.

George Sakoulas1, Kripa Guram2, Katherine Reyes3, Victor Nizet2, Marcus Zervos3.   

Abstract

Bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) USA600 has been associated with increased patient mortality. We found that USA600 MRSA exhibited significantly increased resistance to human cathelicidin LL-37 killing and daptomycin MIC creep compared to non-USA600 MRSA. Virulent health care-associated MRSA strains may coevolve innate host defense peptide and antibiotic resistances.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24648548      PMCID： PMC4042812          DOI： 10.1128/JCM.00189-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  21 in total

1.  USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban Detroit.

Authors:  Carol L Moore; Paola Osaki-Kiyan; Marybeth Perri; Susan Donabedian; Nadia Z Haque; Anne Chen; Marcus J Zervos
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

2.  In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates.

Authors:  Nagendra N Mishra; James McKinnell; Michael R Yeaman; Aileen Rubio; Cynthia C Nast; Liang Chen; Barry N Kreiswirth; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

3.  Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.

Authors:  Natasha E Holmes; John D Turnidge; Wendy J Munckhof; James O Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Wei Gao; Keryn J Christiansen; Geoffrey W Coombs; Paul D R Johnson; Benjamin P Howden
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

Review 4.  A comprehensive summary of LL-37, the factotum human cathelicidin peptide.

Authors:  Dieter Vandamme; Bart Landuyt; Walter Luyten; Liliane Schoofs
Journal:  Cell Immunol       Date:  2012-11-29       Impact factor: 4.868

5.  Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool.

Authors:  Carol L Moore; Mei Lu; Faiqa Cheema; Paola Osaki-Kiyan; Mary Beth Perri; Susan Donabedian; Nadia Z Haque; Marcus J Zervos
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

6.  Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes.

Authors:  Pamela A Moise; Alan Forrest; Arnold S Bayer; Yan Q Xiong; Michael R Yeaman; George Sakoulas
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

7.  Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients.

Authors:  Nagendra N Mishra; Arnold S Bayer; Pamela A Moise; Michael R Yeaman; George Sakoulas
Journal:  J Infect Dis       Date:  2012-08-16       Impact factor: 5.226

8.  Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia.

Authors:  Warren E Rose; Jens C Eickhoff; Sanjay K Shukla; Madhulatha Pantrangi; Suzan Rooijakkers; Sara E Cosgrove; Victor Nizet; George Sakoulas
Journal:  J Infect Dis       Date:  2012-09-10       Impact factor: 5.226

9.  Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?

Authors:  Sebastiaan J van Hal; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2013-03-19       Impact factor: 9.079

10.  Molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in the genomic era: a cross-sectional study.

Authors:  Mattia Prosperi; Nazle Veras; Taj Azarian; Mobeen Rathore; David Nolan; Kenneth Rand; Robert L Cook; Judy Johnson; J Glenn Morris; Marco Salemi
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379
View more
  5 in total

1.  Phenotypes and Virulence among Staphylococcus aureus USA100, USA200, USA300, USA400, and USA600 Clonal Lineages.

Authors:  Jessica M King; Katarina Kulhankova; Christopher S Stach; Bao G Vu; Wilmara Salgado-Pabón
Journal:  mSphere       Date:  2016-06-08       Impact factor: 4.389

2.  Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment.

Authors:  Morgan T Sutton; David Fletcher; Santosh K Ghosh; Aaron Weinberg; Rolf van Heeckeren; Sukhmani Kaur; Zhina Sadeghi; Adonis Hijaz; Jane Reese; Hillard M Lazarus; Donald P Lennon; Arnold I Caplan; Tracey L Bonfield
Journal:  Stem Cells Int       Date:  2016-01-26       Impact factor: 5.443

3.  The structure of the antimicrobial human cathelicidin LL-37 shows oligomerization and channel formation in the presence of membrane mimics.

Authors:  Enea Sancho-Vaello; David Gil-Carton; Patrice François; Eve-Julie Bonetti; Mohamed Kreir; Karunakar Reddy Pothula; Ulrich Kleinekathöfer; Kornelius Zeth
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

Review 4.  Antimicrobial Peptides in Human Sepsis.

Authors:  Lukas Martin; Anne van Meegern; Sabine Doemming; Tobias Schuerholz
Journal:  Front Immunol       Date:  2015-08-20       Impact factor: 7.561

5.  Reduced Production of Bacterial Membrane Vesicles Predicts Mortality in ST45/USA600 Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Somrita Dey; Smitha Gudipati; Christopher Giuliano; Marcus J Zervos; Jonathan M Monk; Richard Szubin; Sarah C J Jorgensen; George Sakoulas; Andrew D Berti
Journal:  Antibiotics (Basel)       Date:  2019-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.